Processa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing Next Generation Chemotherapy (NGC) oncology drug products and addressing unmet medical needs. The company pursues a regulatory science approach to modify the metabolism, distribution, or elimination of existing cancer drugs or their active metabolites while preserving anticancer activity, with a pipeline that includes PCS6422 (NGC-Cap) for metastatic colorectal and breast cancer, PCS3117, PCS499 an oral agent in Phase II for necrobiosis lipoidica, and PCS12852, a selective 5-HT4 receptor agonist in Phase II for post-operative ileus. It also has a license agreement with Akashi Therapeutics to develop PCS100, an anti-fibrotic and anti-inflammatory drug. Founded in 2015, it is based in Hanover, Maryland.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.